Drug Discovery Chemistry Europe 2026
11 November 2026 – 12 November 2026
Intercontinental Barcelona, Barcelona, Spain
Drug Discovery Chemistry Europe, organised by Cambridge Healthtech Institute and now in its 3rd annual edition, is an in-person and virtual conference for discovery chemists, biologists and computational scientists from pharma, biotech and academia, held 10-12 November 2026 at the InterContinental Barcelona. The programme is structured around four tracks - Lead Generation Strategies and AI/ML for Drug Discovery (10-11 November), and Next-Gen Degraders: Glues & Conjugates and Targeting PPIs with Peptides & Small Molecules (11-12 November) - with shared plenary sessions, breakout discussions, posters and an exhibit hall.
92 sessions · 90 speakers
Organiser (1)
Cambridge Healthtech Institute
Media Partners (4)
Medhealth Outlook · Icon Outlook Magazine · Universitat Pompeu Fabra (UPF) · Enterprise Viewpoint
Sponsors (12)
NEOsphere Biotechnologies · PharmaBlock · Royal Society of Chemistry · Pelago Bioscience · Chemotargets · Optibrium · PozeSCAF · Merck Life Science · Elsevier · MolPort · QC Ware · Promega
Exhibitor (1)
Agenda
- Chairperson's Remarks: Ai/Ml For Expanding Chemical Space 10 November 2026
- Chairperson's Remarks: Biophysical & Computational Approaches For Lead Generation 10 November 2026
- FEATURED PRESENTATION: Integrated Hit Discovery for DNPH1: Applying Multiple Hit-Finding Platforms to Tackle a Challenging Oncology Drug Target 10 November 2026
- Accurate Docking Meets AI/ML Tools to Walk through Vast Chemical Spaces: From Idea to Clinic 10 November 2026
- Measuring Stable Interactions by SPR: Addressing the Long Residence-Time Challenge 10 November 2026
- Scaling Physics-Based Methods with AI for CNS Drug Discovery 10 November 2026
- FEATURED PRESENTATION: No Target Left behind: Covalent AI Meets the Undruggable Proteome 10 November 2026
- Active Learning Virtual Screening for Crop Protection 10 November 2026
- Co-Folding Application in Compound Optimisation: Impact on DMTA Cycle Reduction 10 November 2026
- Direct-to-Biology for WRN-Targeted Covalent Hit Identification and Optimisation 10 November 2026
- AI-Driven and Quantum-Enhanced Discovery of CMG Helicase Inhibitors 10 November 2026
- Discovery of Covalent PARG Inhibitors through Scaffold Hopping and the Use of an Underexplored Bicyclo[1.1.0]butane Carboxamide Warhead 10 November 2026
- Structure-Based Development of the First Covalent Inhibitor of the Monopolar Spindle Kinase 1 (MPS1/TTK) 10 November 2026
- De novo Design of Oral and Cell-Permeable Peptides Using Generative AI 10 November 2026
- Beyond Endpoint Assays: Label-Free Kinetics for Covalent Hits, DEL Hits, PROTACs and Antibodies 10 November 2026
- From Memorisation to Extrapolation: Expanding Chemical Space with AI and Quantum Chemistry 10 November 2026
- Beyond Binding: How Pelago Bioscience Uses CETSA to Guide Hit-to-Lead Decisions 10 November 2026
- Chairperson's Remarks: Trends In Ai/Ml-Driven Drug Discovery 10 November 2026
- Chairperson's Remarks: Fragment-Based Approaches 10 November 2026
- Fragment-Based Discovery Establishes Ligandability of the Transcription Factor MITF 10 November 2026
- OpenBind: Unlocking Protein-Ligand Binding Prediction 10 November 2026
- Frag2Drug—A New Open-Access Fragment-Screening and Drug Discovery Platform Based on SPR and X-Ray Crystallography 10 November 2026
- OpenFold3 and Beyond: Fully Open Source Co-Folding Model for Discovery 10 November 2026
- Panel Discussion: How are AI/ML Techniques Impacting Drug Discovery in Pharma? 10 November 2026
- Fragment-Based Approaches for Challenging Targets: Insights and Learnings 10 November 2026
- Talk Title to be Announced 10 November 2026
- BRETSA: A Sensitive, Tracer-Free, and Scalable BRET Method for Measuring Target Engagement in Live Cells 10 November 2026
- Structural Proteomics and AI Platform Enables Degrader Rational Design 10 November 2026
- FEATURED PRESENTATION: Native Mass Spectrometry Analysis of a Cullin RING Ubiquitin E3 Ligase Complex in the Context of Targeted Protein Degradation 10 November 2026
- Proximity Binding Assay for PROTAC Ternary Complex Analysis 10 November 2026
- Computational Strategies for Degrader Discovery & Optimisation 10 November 2026
- AI/ML- True Impact in Drug Discovery Today 10 November 2026
- AI for Drug Design and Lead Optimization 10 November 2026
- DEL (DNA-Encoded Library) Developments 10 November 2026
- Direct-to-Biology (D2B) Applications for Degrader and Small Molecule Lead Generation 10 November 2026
- Welcome Remarks by Lead Event Director 11 November 2026
- PLENARY KEYNOTE: Harnessing EpiProteome Modulation for Drug Discovery 11 November 2026
- Chairperson's Remarks: Del Or D2B Applications For Degraders & Difficult Targets 11 November 2026
- Chairperson's Remarks: Federated Ai Models & Impact On Discovery 11 November 2026
- Discovery of Molecular Glues from an FKBP12-Focused DNA-Encoded Library 11 November 2026
- A Foundational Shift in AI-driven Drug Discovery: Improving Co-Folding Models with Federated Networks 11 November 2026
- Crossing the Data Chasm in Biological Foundation Models 11 November 2026
- Novel Small Molecule Discovery against a Multi-Span Membrane Protein via DNA-Encoded Library Technology 11 November 2026
- De-risking Drug Development Through Biological and Artificial Intelligence 11 November 2026
- Three Impactful Problems in Drug Discovery That Might be Solvable with Machine Learning 11 November 2026
- Panel Discussion: From Molecules to Medicines: How AI Foundation Models are Reshaping Drug Discovery 11 November 2026
- A Modular Photo-Redox Assisted Direct-to-Biology Approach for Bifunctional Degrader Synthesis and Discovery 11 November 2026
- Two Ways to Be Wrong: What AI-Ready Data Doesn't Fix 11 November 2026
- How Innovative DEL Designs Lead to Clinical Candidates and Powerful Data-Driven Workflows 11 November 2026
- Chairperson's Remarks: Macrocyclic Peptides: Discovery, Design, Optimisation 11 November 2026
- Chairperson's Remarks: Induced Proximity Strategies 11 November 2026
- FEATURED PRESENTATION: Optimisation of the Solubility and Potency of Macrocycles through Physics-Based Simulations 11 November 2026
- Discovery of a Covalent Molecular Glue of Rac1, and its Exchange Factor, Kalirin 11 November 2026
- Pure-DEL: DNA-Encoded Libraries to Discover Small Macrocyclic Peptides with Drug Potential 11 November 2026
- Rewiring Transcription via Induced Proximity 11 November 2026
- Disease-Network-Guided Identification of Molecular Glue Pair Opportunities 11 November 2026
- Reducing Synthetic Effort by Up to 90%: A Retrospective Computational Study of a Macrocyclic PD-(L)1 Inhibitor 11 November 2026
- Induced-Proximity Approaches for Targeted Protein Degradation and Dephosphorylation 11 November 2026
- Constraining Peptides and Proteins inside Living Cells for Functional PPI Discovery 11 November 2026
- Drugging Cyclin A/B Protein–Protein Interactions with Orally Bioavailable Macrocycles: From Structure-Guided Design to Clinical Translation 11 November 2026
- FEATURED PRESENTATION: Targeting Post-Translational Modifications through Induced Proximity and Chemical Biology 11 November 2026
- Proteomics-Driven AI/ML Powers Rational Molecular Glue Degrader Discovery 11 November 2026
- Talk Title to be Announced 11 November 2026
- Designing and Optimizing Molecular Glues and Proximity-based Drugs 11 November 2026
- Novel Degrader Modalities, Ligases for Pursuing Challenging Drug Targets 11 November 2026
- Peptide Design Innovations 11 November 2026
- Biophysical Approaches for Small Molecule Lead Generation 11 November 2026
- Chairperson's Remarks: SMALL MOLECULE LEADS FOR INTRACELLULAR PPIs 12 November 2026
- Chairperson's Remarks: Tools For Developing Next-Gen Degraders 12 November 2026
- Integrating Fragment Screening and Covalent Chemistry to Drug DNA-Binding Proteins: RAD52 as a Case Study 12 November 2026
- TRIM21 E3 Ligase as a Platform for PROTACs and Molecular Glues 12 November 2026
- Identification and Optimisation of Fragment-Derived and DEL-Truncated Inhibitors Targeting Novel Allosteric Sites on the WRN Helicase 12 November 2026
- Stereoselective Degradation of Lipid Kinases 12 November 2026
- 14-3-3 Molecular Stabilisation of Parkinson's Disease Target LRRK2 12 November 2026
- Atypical Ubiquitin E3 Ligases: New Therapeutic Opportunities and How to Test Them 12 November 2026
- Tackling Intrinsically Disordered Proteins: A Novel Peptide Disrupting the p53–FOXO4 Interaction 12 November 2026
- Cracking the CNS Barrier for PROTACs: Lessons from Literature and Emerging Design Principles 12 November 2026
- PROTACs in Respiratory Disease: Opportunities for Inhaled Delivery 12 November 2026
- Unlocking the Druggability of Disordered Oncogenic Transcription Factors to Deliver Transformative Targeted Cancer Therapies 12 November 2026
- Unlocking the Prospective Design of Non-Degrading Macrocyclic Glues with AI 12 November 2026